Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Cleveland Clinic Journal of Medicine. 2004 August;71(8):609-616
August 1, 2004|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTThe Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.
